|
業務類別
|
Biotechnology |
|
業務概覽
|
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds. |
| 公司地址
| 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9 |
| 電話號碼
| +1 877 361-4003 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.helus.com |
| 員工數量
| 50 |
| Mr. Aaron Bartlone |
Chief Operation Officer |
-- |
01/07/2025 |
| Mr. Paul Glavine |
Director and Chief Growth Officer |
加元 724.55K |
01/07/2025 |
| Mr. Greg Cavers |
Chief Financial Officer |
加元 503.16K |
01/07/2025 |
| Mr. Gabriel Fahel |
Chief Legal Officer and Corporate Secretary |
美元 528.32K |
01/07/2025 |
| Mr. George Tziras |
Director and Chief Business Officer |
-- |
01/07/2025 |
| Mr. Eric So |
Director, President and Interim Chief Executive Officer |
加元 724.55K |
02/09/2025 |
|
|
| Mr. Mark Lawson |
Independent Director |
01/07/2025 |
| Ms. Theresa Firestone |
Lead Independent Director |
01/07/2025 |
| Mr. Grant Froese |
Independent Director |
01/07/2025 |
| Mr. Paul Glavine |
Director and Chief Growth Officer |
01/07/2025 |
| Dr. Eric Hoskins |
Independent Director |
01/07/2025 |
| Mr. George Tziras |
Director and Chief Business Officer |
01/07/2025 |
| Mr. Eric So |
Director, President and Interim Chief Executive Officer |
02/09/2025 |
|
|
|
|
